Literature DB >> 25156912

GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro.

Xu Zhang1,2, Zhijun Ding3, Jianbing Mo3, Ben Sang3, Qiong Shi1,2, Jinxia Hu1,2, Shao Xie1,2, Wenjian Zhan1,2, Dong Lu3, Minglin Yang3, Wenbin Bian3, Xiuping Zhou1,2, Rutong Yu1,2.   

Abstract

The identification of genes involved in carcinogenesis and tumor progression is of great interest, since these genes might be possible as candidates for new tumor targeted therapy strategies. Our previous study shows that Golgi phosphoprotein 3 (GOLPH3) is involved in glioma cell migration and invasion, the critical characteristics of malignant gliomas. In this study, we explored the mechanism of GOLPH3 affecting cell migration and invasion and found that GOLPH3 promotes glioblastoma (GBM) cell migration and invasion via the mammalian target of rapamycin(mTOR)-Y-box binding protein-1 (YB1) pathway in vitro. Both the protein levels of GOLPH3 and YB1 were up-regulated in human glioma tissues and they exhibited direct correlation with each other. In addition, down-regulation of GOLPH3 inhibited glioma cell migration and invasion, while over-expression of GOLPH3 enhanced them. Meanwhile, GOLPH3 down-regulation led to a significant decrease of YB1 level as well as mTOR activity, both required for glioma cell migration and invasion. On the contrary, YB1 level and mTOR activity increased after GOLPH3 over-expression. YB1 down-regulation or mTOR ATP site inhibitor INK128 treatment inhibited cell migration and invasion, similar to the effect of GOLPH3 down-regulation. Furthermore, over-expression of GOLPH3 induced glioma cell migration and invasion was blocked by INK128 and YB1 down-regulation. Taken together, these results show that GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1pathway, indicating that GOLPH3-mTOR-YB1 pathway might be a new therapeutic target for glioma treatment.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  GOLPH3; YB1; glioma; invasion; mTOR; migration

Mesh:

Substances:

Year:  2014        PMID: 25156912     DOI: 10.1002/mc.22197

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  31 in total

Review 1.  GOLPH3 links the Golgi, DNA damage, and cancer.

Authors:  Matthew D Buschman; Juliati Rahajeng; Seth J Field
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

Review 2.  GOLPH3: a Golgi phosphatidylinositol(4)phosphate effector that directs vesicle trafficking and drives cancer.

Authors:  Ramya S Kuna; Seth J Field
Journal:  J Lipid Res       Date:  2018-09-28       Impact factor: 5.922

3.  GOLPH3 promotes glioma progression via facilitating JAK2-STAT3 pathway activation.

Authors:  Shishuang Wu; Jiale Fu; Yu Dong; Qinghao Yi; Dong Lu; Weibing Wang; Yanhua Qi; Rutong Yu; Xiuping Zhou
Journal:  J Neurooncol       Date:  2018-04-30       Impact factor: 4.130

4.  LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.

Authors:  Yi Shi; Decheng Geng; Yu Zhang; Min Zhao; Yan Wang; Yang Jiang; Rutong Yu; Xiuping Zhou
Journal:  J Mol Neurosci       Date:  2019-02-15       Impact factor: 3.444

5.  High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer.

Authors:  Xuebing Yan; Leilei Yan; Jia Zhou; Sihong Liu; Zezhi Shan; Chunyu Jiang; Yuan Tian; Zhiming Jin
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 6.  Golgi phosphoprotein3 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis.

Authors:  Yaqi Jiang; Yuqi Su; Yang Zhao; Changqie Pan; Li Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  GOLPH3 promotes glioma progression by enhancing PHB2-mediated autophagy.

Authors:  Kai Wang; Yanhua Qi; Xu Wang; Yushuai Liu; Min Zhao; Ding Zhou; Yu Zhang; Yan Wang; Rutong Yu; Xiuping Zhou
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

Authors:  Clare F Malone; Chloe Emerson; Rachel Ingraham; William Barbosa; Stephanie Guerra; Haejin Yoon; Lin L Liu; Franziska Michor; Marcia Haigis; Kay F Macleod; Ophélia Maertens; Karen Cichowski
Journal:  Cancer Discov       Date:  2017-09-29       Impact factor: 39.397

9.  Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes.

Authors:  Zixuan Yuan; Liang Zhao; Yafei Zhang; Shun Li; Bomin Pan; Lei Hua; Zhen Wang; Chengkun Ye; Jun Lu; Rutong Yu; Hongmei Liu
Journal:  J Neurooncol       Date:  2018-08-13       Impact factor: 4.130

10.  Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.

Authors:  Xiuping Zhou; Shao Xie; Shishuang Wu; Yanhua Qi; Zhaohao Wang; Hao Zhang; Dong Lu; Xu Wang; Yu Dong; Guanzheng Liu; Dongxu Yang; Qiong Shi; Wenbin Bian; Rutong Yu
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.